Valuation : Neurocrine Biosciences, Inc.

Market Cap 15.82B 13.61B 12.81B 11.7B 21.89B 1,494B 21.95B 151B 58.73B 766B 59.41B 58.11B 2,469B P/E 2026 *
22.1x
P/E 2027 * 15.4x
Enterprise Value 14.17B 12.19B 11.47B 10.48B 19.6B 1,338B 19.66B 136B 52.6B 686B 53.21B 52.05B 2,211B EV / Sales 2026 *
3.63x
EV / Sales 2027 * 2.84x
Free-Float
98.94%
Yield 2026 *
-
Yield 2027 * -
1 day-1.71%
1 week+1.03%
Current month+1.05%
1 month-2.62%
3 months-5.03%
6 months+21.47%
Current year+9.74%
1 week 153.7
Extreme 153.7001
160.42
1 month 148.78
Extreme 148.775
165.46
Current year 122.14
Extreme 122.1375
186.12
1 year 122.14
Extreme 122.1375
186.12
3 years 84.23
Extreme 84.23
186.12
5 years 71.88
Extreme 71.875
186.12
10 years 37.34
Extreme 37.345
186.12
Manager TitleAgeSince
Chief Executive Officer 53 2024-10-10
Director of Finance/CFO 46 2017-10-31
Chief Tech/Sci/R&D Officer - 2025-06-08
Director TitleAgeSince
Director/Board Member 68 2007-12-31
Director/Board Member 64 1998-03-31
Chairman 78 2011-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Don

Director

-1,000 0.0010%
8/4/26 Don

Chief Technology Officer

-2,409 0.0024%
7/29/26 Exercice

Director

1,684 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-1.71%+1.03%+8.01%+41.27% 15.82B
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
-0.55%+0.62%+31.43%+38.32% 352B
-2.39%+2.37%+23.32%+42.37% 304B
+1.59%+2.01%+1.94%+12.73% 252B
-1.55%+1.11%+54.15%+75.59% 236B
-0.04%+2.19%-13.88%-55.82% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -0.82%+1.24%+26.92%+51.34% 369.42B
Weighted average by Cap. -0.88%+0.62%+37.73%+67.01%

Financials

2026 *2027 *
Net sales 3.9B 3.36B 3.16B 2.89B 5.4B 368B 5.41B 37.33B 14.49B 189B 14.65B 14.33B 609B 4.55B 3.92B 3.69B 3.37B 6.3B 430B 6.32B 43.56B 16.9B 221B 17.1B 16.73B 711B
Net income 740M 637M 599M 547M 1.02B 69.88B 1.03B 7.08B 2.75B 35.85B 2.78B 2.72B 116B 1.03B 889M 837M 764M 1.43B 97.55B 1.43B 9.88B 3.84B 50.05B 3.88B 3.8B 161B
Net Debt -1.65B -1.42B -1.34B -1.22B -2.29B -156B -2.29B -15.8B -6.13B -80.01B -6.2B -6.07B -258B -2.87B -2.47B -2.32B -2.12B -3.97B -271B -3.98B -27.46B -10.66B -139B -10.78B -10.54B -448B
Logo Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others.
Employees
2,500
Date Price Change Volume
26-09-04 US$155.64 -1.71% 933,569
26-09-03 US$158.35 +0.35% 758,262
26-09-02 US$157.79 +0.66% 1,037,887
26-09-01 US$156.76 +1.77% 878,438
26-08-31 US$154.03 -0.02% 1,741,100
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
155.64USD
Average target price
211.72USD
Spread / Average Target
+36.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NBIX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!